ACCELERON PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 118 rows in 2015. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2015-01-08: Reporting owner KANIA EDWIN M JR; Form 4/A; Security Option to Purchase Common Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2015-01-08: Reporting owner Nader Francois; Form 4; Security Option to Purchase Common Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2015-01-08: Reporting owner Kearney Terrence C; Form 4; Security Option to Purchase Common Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2015-01-08: Reporting owner POPS RICHARD F; Form 4; Security Option to Purchase Common Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2015-01-08 | KANIA EDWIN M JR Director | 4/A | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $41.20 exercise price | 2015-04-08 | |
| 2015-01-08 | Nader Francois Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +576 576 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Kearney Terrence C Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,665 4,665 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | POPS RICHARD F Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Zakrzewski Joseph S Director | 4 | Option to purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Maniatis Tom Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | George Jean Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | MCGUIRE TERRANCE Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | KANIA EDWIN M JR Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Quisel John D Officer (SVP Gen. Counsel & Secretary) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,000 41,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Kumar Ravindra Officer (VP & Chief Scientific Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,000 41,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Ertel Steven D Officer (SVP & Chief Business Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,000 41,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Sherman Matthew L Officer (SVP & Chief Medical Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,000 41,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | MCLAUGHLIN KEVIN F Officer (SVP, CFO and Treasurer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,000 41,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-08 | Knopf John L Director, Officer (CEO and President) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +151,000 151,000 owned after | $41.20 exercise price | 2015-01-09 | |
| 2015-01-07 | MCLAUGHLIN KEVIN F Officer (SVP, CFO and Treasurer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 105,751 owned after | $3.88 exercise price | 2015-01-09 | |
| 2015-01-02 | Ertel Steven D Officer (SVP & Chief Business Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 6,094 owned after | $1.80 exercise price | 2015-01-05 | |
| 2015-01-02 | Kumar Ravindra Officer (VP & Chief Scientific Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,000 4,500 owned after | $5.88 exercise price | 2015-01-05 |